PMC:7100515 / 26805-29045 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T234","span":{"begin":477,"end":482},"obj":"Body_part"},{"id":"T235","span":{"begin":527,"end":532},"obj":"Body_part"},{"id":"T236","span":{"begin":1157,"end":1162},"obj":"Body_part"},{"id":"T237","span":{"begin":1239,"end":1244},"obj":"Body_part"},{"id":"T238","span":{"begin":1575,"end":1580},"obj":"Body_part"},{"id":"T239","span":{"begin":1960,"end":1968},"obj":"Body_part"},{"id":"T240","span":{"begin":2000,"end":2005},"obj":"Body_part"},{"id":"T241","span":{"begin":2007,"end":2012},"obj":"Body_part"},{"id":"T242","span":{"begin":2106,"end":2111},"obj":"Body_part"}],"attributes":[{"id":"A234","pred":"fma_id","subj":"T234","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A235","pred":"fma_id","subj":"T235","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A236","pred":"fma_id","subj":"T236","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A237","pred":"fma_id","subj":"T237","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A238","pred":"fma_id","subj":"T238","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A239","pred":"fma_id","subj":"T239","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A240","pred":"fma_id","subj":"T240","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A241","pred":"fma_id","subj":"T241","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A242","pred":"fma_id","subj":"T242","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Cross-neutralization of SARS and COVID-19 patient sera\nAs rabbit polyclonal anti-SARS S1 antibodies did not show significant neutralization activity against SARS-CoV-2 S pseudovirions, we then asked whether sera from recovered SARS and COVID-19 patients could neutralize SARS-CoV S and SARS-CoV-2 S pseudovirions. We obtained sera from one recovered SARS patient and five recovered COVID-19 patients and tested their neutralization activities against transduction on 293/hACE2 cells by SARS-CoV and SARS-CoV-2 S pseudovirions. Serum from recovered SARS patient showed strong inhibition on transduction by SARS-CoV S pseudovirions, and it had modest neutralization activity against SARS-CoV-2 S pseudovirons (Fig. 6a and Table 1). In contrast, sera from all five COVID-19 patients neutralized SARS-CoV-2 S pseudovirions effectively, and none of them had an effect on transduction by SARS-CoV S pseudovirions (Fig. 6b and Table 1).\nFig. 6 Limited cross-neutralization of SARS and COVID-19 sera.\nAll sera were incubated on 56 °C for 30 min to eliminate complement. SARS-CoV S and SARS-CoV-2 S pseudovirons were pre-incubated with serially diluted SARS patient serum (a) or COVID-19 patient sera (b) for 1 h on ice and then added on 293/hACE2 cells. Pseudoviral transduction was measured 40 h later. Experiments were done in triplicates and repeated twice, and one representative is shown. Error bars indicate SEM of technical triplicates. Source data are provided as a Source Data file.\nTable 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":527,"end":532},"obj":"Body_part"},{"id":"T7","span":{"begin":1157,"end":1162},"obj":"Body_part"},{"id":"T8","span":{"begin":1575,"end":1580},"obj":"Body_part"},{"id":"T9","span":{"begin":2106,"end":2111},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Cross-neutralization of SARS and COVID-19 patient sera\nAs rabbit polyclonal anti-SARS S1 antibodies did not show significant neutralization activity against SARS-CoV-2 S pseudovirions, we then asked whether sera from recovered SARS and COVID-19 patients could neutralize SARS-CoV S and SARS-CoV-2 S pseudovirions. We obtained sera from one recovered SARS patient and five recovered COVID-19 patients and tested their neutralization activities against transduction on 293/hACE2 cells by SARS-CoV and SARS-CoV-2 S pseudovirions. Serum from recovered SARS patient showed strong inhibition on transduction by SARS-CoV S pseudovirions, and it had modest neutralization activity against SARS-CoV-2 S pseudovirons (Fig. 6a and Table 1). In contrast, sera from all five COVID-19 patients neutralized SARS-CoV-2 S pseudovirions effectively, and none of them had an effect on transduction by SARS-CoV S pseudovirions (Fig. 6b and Table 1).\nFig. 6 Limited cross-neutralization of SARS and COVID-19 sera.\nAll sera were incubated on 56 °C for 30 min to eliminate complement. SARS-CoV S and SARS-CoV-2 S pseudovirons were pre-incubated with serially diluted SARS patient serum (a) or COVID-19 patient sera (b) for 1 h on ice and then added on 293/hACE2 cells. Pseudoviral transduction was measured 40 h later. Experiments were done in triplicates and repeated twice, and one representative is shown. Error bars indicate SEM of technical triplicates. Source data are provided as a Source Data file.\nTable 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

LitCovid-PD-MONDO

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T217","span":{"begin":1969,"end":1976},"obj":"Chemical"}],"attributes":[{"id":"A217","pred":"chebi_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/CHEBI_60004"}],"text":"Cross-neutralization of SARS and COVID-19 patient sera\nAs rabbit polyclonal anti-SARS S1 antibodies did not show significant neutralization activity against SARS-CoV-2 S pseudovirions, we then asked whether sera from recovered SARS and COVID-19 patients could neutralize SARS-CoV S and SARS-CoV-2 S pseudovirions. We obtained sera from one recovered SARS patient and five recovered COVID-19 patients and tested their neutralization activities against transduction on 293/hACE2 cells by SARS-CoV and SARS-CoV-2 S pseudovirions. Serum from recovered SARS patient showed strong inhibition on transduction by SARS-CoV S pseudovirions, and it had modest neutralization activity against SARS-CoV-2 S pseudovirons (Fig. 6a and Table 1). In contrast, sera from all five COVID-19 patients neutralized SARS-CoV-2 S pseudovirions effectively, and none of them had an effect on transduction by SARS-CoV S pseudovirions (Fig. 6b and Table 1).\nFig. 6 Limited cross-neutralization of SARS and COVID-19 sera.\nAll sera were incubated on 56 °C for 30 min to eliminate complement. SARS-CoV S and SARS-CoV-2 S pseudovirons were pre-incubated with serially diluted SARS patient serum (a) or COVID-19 patient sera (b) for 1 h on ice and then added on 293/hACE2 cells. Pseudoviral transduction was measured 40 h later. Experiments were done in triplicates and repeated twice, and one representative is shown. Error bars indicate SEM of technical triplicates. Source data are provided as a Source Data file.\nTable 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T48","span":{"begin":451,"end":463},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T49","span":{"begin":589,"end":601},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T50","span":{"begin":866,"end":878},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T51","span":{"begin":1258,"end":1270},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T52","span":{"begin":2051,"end":2063},"obj":"http://purl.obolibrary.org/obo/GO_0009293"},{"id":"T53","span":{"begin":2134,"end":2146},"obj":"http://purl.obolibrary.org/obo/GO_0009293"}],"text":"Cross-neutralization of SARS and COVID-19 patient sera\nAs rabbit polyclonal anti-SARS S1 antibodies did not show significant neutralization activity against SARS-CoV-2 S pseudovirions, we then asked whether sera from recovered SARS and COVID-19 patients could neutralize SARS-CoV S and SARS-CoV-2 S pseudovirions. We obtained sera from one recovered SARS patient and five recovered COVID-19 patients and tested their neutralization activities against transduction on 293/hACE2 cells by SARS-CoV and SARS-CoV-2 S pseudovirions. Serum from recovered SARS patient showed strong inhibition on transduction by SARS-CoV S pseudovirions, and it had modest neutralization activity against SARS-CoV-2 S pseudovirons (Fig. 6a and Table 1). In contrast, sera from all five COVID-19 patients neutralized SARS-CoV-2 S pseudovirions effectively, and none of them had an effect on transduction by SARS-CoV S pseudovirions (Fig. 6b and Table 1).\nFig. 6 Limited cross-neutralization of SARS and COVID-19 sera.\nAll sera were incubated on 56 °C for 30 min to eliminate complement. SARS-CoV S and SARS-CoV-2 S pseudovirons were pre-incubated with serially diluted SARS patient serum (a) or COVID-19 patient sera (b) for 1 h on ice and then added on 293/hACE2 cells. Pseudoviral transduction was measured 40 h later. Experiments were done in triplicates and repeated twice, and one representative is shown. Error bars indicate SEM of technical triplicates. Source data are provided as a Source Data file.\nTable 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T192","span":{"begin":0,"end":54},"obj":"Sentence"},{"id":"T193","span":{"begin":55,"end":313},"obj":"Sentence"},{"id":"T194","span":{"begin":314,"end":526},"obj":"Sentence"},{"id":"T195","span":{"begin":527,"end":729},"obj":"Sentence"},{"id":"T196","span":{"begin":730,"end":929},"obj":"Sentence"},{"id":"T197","span":{"begin":930,"end":992},"obj":"Sentence"},{"id":"T198","span":{"begin":993,"end":1061},"obj":"Sentence"},{"id":"T199","span":{"begin":1062,"end":1245},"obj":"Sentence"},{"id":"T200","span":{"begin":1246,"end":1295},"obj":"Sentence"},{"id":"T201","span":{"begin":1296,"end":1385},"obj":"Sentence"},{"id":"T202","span":{"begin":1386,"end":1435},"obj":"Sentence"},{"id":"T203","span":{"begin":1436,"end":1483},"obj":"Sentence"},{"id":"T204","span":{"begin":1484,"end":1566},"obj":"Sentence"},{"id":"T205","span":{"begin":1567,"end":1630},"obj":"Sentence"},{"id":"T206","span":{"begin":1631,"end":1654},"obj":"Sentence"},{"id":"T207","span":{"begin":1655,"end":1691},"obj":"Sentence"},{"id":"T208","span":{"begin":1692,"end":1727},"obj":"Sentence"},{"id":"T209","span":{"begin":1728,"end":1764},"obj":"Sentence"},{"id":"T210","span":{"begin":1765,"end":1801},"obj":"Sentence"},{"id":"T211","span":{"begin":1802,"end":1838},"obj":"Sentence"},{"id":"T212","span":{"begin":1839,"end":2006},"obj":"Sentence"},{"id":"T213","span":{"begin":2007,"end":2077},"obj":"Sentence"},{"id":"T214","span":{"begin":2078,"end":2192},"obj":"Sentence"},{"id":"T215","span":{"begin":2193,"end":2240},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Cross-neutralization of SARS and COVID-19 patient sera\nAs rabbit polyclonal anti-SARS S1 antibodies did not show significant neutralization activity against SARS-CoV-2 S pseudovirions, we then asked whether sera from recovered SARS and COVID-19 patients could neutralize SARS-CoV S and SARS-CoV-2 S pseudovirions. We obtained sera from one recovered SARS patient and five recovered COVID-19 patients and tested their neutralization activities against transduction on 293/hACE2 cells by SARS-CoV and SARS-CoV-2 S pseudovirions. Serum from recovered SARS patient showed strong inhibition on transduction by SARS-CoV S pseudovirions, and it had modest neutralization activity against SARS-CoV-2 S pseudovirons (Fig. 6a and Table 1). In contrast, sera from all five COVID-19 patients neutralized SARS-CoV-2 S pseudovirions effectively, and none of them had an effect on transduction by SARS-CoV S pseudovirions (Fig. 6b and Table 1).\nFig. 6 Limited cross-neutralization of SARS and COVID-19 sera.\nAll sera were incubated on 56 °C for 30 min to eliminate complement. SARS-CoV S and SARS-CoV-2 S pseudovirons were pre-incubated with serially diluted SARS patient serum (a) or COVID-19 patient sera (b) for 1 h on ice and then added on 293/hACE2 cells. Pseudoviral transduction was measured 40 h later. Experiments were done in triplicates and repeated twice, and one representative is shown. Error bars indicate SEM of technical triplicates. Source data are provided as a Source Data file.\nTable 1 Neutralization activities of antisera from SARS-CoV and COVID-19 patients.\nPatient serum SARS-CoV S pseudovirion SARS-CoV-2 S pseudovirion\nSARS-CoV patient \u003e80 40\nCOVID-19 patient #1 Not detected \u003e80\nCOVID-19 patient #2 Not detected 40\nCOVID-19 patient #3 Not detected \u003e80\nCOVID-19 patient #4 Not detected \u003e80\nCOVID-19 patient #5 Not detected \u003e80\nSARS-CoV and SARS-CoV-2 S pseudovirions were pre-incubated with serially diluted patient sera for 1 h on ice, then virus-antibody mixture was added on 293/hACE2 cells. Cells were lysed 40 h later and pseudovirus transduction was measured. The highest dilution of the serum sample that decreased transduction by 50% or more was considered to be positive. Source data are provided as a Source Data file."}

LitCovid-PubTator

PMC:7100515 / 26805-29045 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7100515 / 26805-29045 JSON TXT